Reversible binocular visual loss in temporal association with artesunate-amodiaquine treatment in a child on mefloquine chemoprophylaxis.

dc.contributor.authorAdjei, G.O.
dc.contributor.authorAdabayeri, V.M.
dc.contributor.authorAnnobil, S.H.
dc.date.accessioned2019-01-11T13:45:08Z
dc.date.available2019-01-11T13:45:08Z
dc.date.issued2012-09
dc.description.abstractA case of an acute reversible visual loss in a 10-year-old child who was on mefloquine prophylaxis, and was treated with artesunate-amodiaquine for an acute febrile illness diagnosed clinically as uncomplicated malaria, is reported. On admission the patient could not perceive light and had bilateral papilloedema. She was treated with dexamethasone and recovered her sight gradually over a 21-day period. There has been no previous report to our knowledge, of an association between acute visual loss and mefloquine, amodiaquine, or artesunate in the published literature, even though mefloquine is associated with blurring of vision, and antimalarials of the quinoline class have been associated with retinopathy (during long term use). While causality is difficult to ascribe in this case, it may be prudent to avoid the use of quinoline-based antimalarials for treating acute malaria in travelers taking mefloquine prophylaxis, because information on the safety of concurrent use of artemisinin combination therapies and mefloquine, or other recommended prophylactic regimens, is limited.en_US
dc.identifier.otherVol. 46(3): pp 171-3
dc.identifier.urihttp://ugspace.ug.edu.gh/handle/123456789/26778
dc.language.isoenen_US
dc.publisherGhana medical journalen_US
dc.subjectReversible binocular visualen_US
dc.subjectartesunate-amodiaquineen_US
dc.subjecttreatmenten_US
dc.subjectmefloquine chemoprophylaxisen_US
dc.titleReversible binocular visual loss in temporal association with artesunate-amodiaquine treatment in a child on mefloquine chemoprophylaxis.en_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description: